{"id":"ct-p47","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4297274","moleculeType":"Small molecule","molecularWeight":"533.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P47 is a PD-L1 checkpoint inhibitor developed as a biosimilar or novel anti-PD-L1 therapeutic. By blocking the PD-L1/PD-1 axis, it prevents tumor cells from suppressing T-cell mediated immunity, thereby reactivating the body's anti-tumor immune response. This mechanism is used to treat various solid tumors and hematologic malignancies.","oneSentence":"CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:03.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05489224","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-09-14","conditions":"Rheumatoid Arthritis","enrollment":471},{"nctId":"NCT05617183","phase":"PHASE1","title":"Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2022-11-15","conditions":"Healthy Subjects","enrollment":268},{"nctId":"NCT05725434","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2023-02-06","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05188378","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2021-12-22","conditions":"Healthy Subjects","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P47","genericName":"CT-P47","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}